Anti - S100A4 Antibodies for the Treatment of Systemic Sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F20%3AN0000009" target="_blank" >RIV/00023728:_____/20:N0000009 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Anti - S100A4 Antibodies for the Treatment of Systemic Sclerosis
Original language description
Herein are disclosed anti-S100A4 antibodies useful for the treatment of the disease systemic sclerosis. The disclosure also provides isolated polynucleotides, vectors, isolated host cells, compositions and pharmaceutical compositions for the treatment of 5 systemic sclerosis
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
30226 - Rheumatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
20183251.6-1111
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Jun 30, 2020
Owner name
Jor Klingelhöfer, Jonas Hallén, Rizwan Hussain, Jörg Hans Wilhelm Distler FibroCure, Michal Tomčík Revmatologický ústav
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
O - Doposud nevyužívaný výsledek